Molecular Markers In Forecasting The Clinical Efficacy Of Infliximab In Psoriasis Patients


如何引用文章

全文:

详细

Biosamples (skin tissue samples taken from affection foci and blood serum) from 22 patients suffering from severe to medium psoriasis (8 women and 14 men) aged 19-57 treated with Infliximab were analyzed. As for skin tissue samples, the molecular structure of genes TNF-a, TNF-R-I and TNF-R-II, contents of cytokine TNF-a and its soluble receptors (sTNF-RI and sTNF-RII) and proteome composition was analyzed in skin tissue samples; contents of TNF-a, IL2, IL4, IL6, IL-8 and IL-10 were analyzed in the blood serum. The homozygous TT genotype of TNF-R-II gene at the 676 locus and high IL10 level in the blood serum (>2.7 pg/ml) was associated with the high intensity of the psoriasis patient response to treatment with Infliximab; the homozygous GG genotype of TNF-R-II gene at the 676 locus and low level of IL10 in the blood serum (<1.0 pg/ml) was associated with a weak response or no response to treatment with Infliximab. These results laid the basis for developing a method to forecast the treatment efficacy in psoriasis patients based on a genetically engineered biological drug - Infliximab.
Pilot results indicating a possible mutual relation between the composition of the skin proteome and psoriasis patient's therapeutic response to treatment with Infliximab have been obtained.

作者简介

A KUBANOVA

ФГУ «ГНЦД Росмедтехнологий», г. Москва

директоракадемик РАМН, д.м.н., профессор; ФГУ «ГНЦД Росмедтехнологий», г. Москва

I LESNAYA

ФГУ «ГНЦД Росмедтехнологий», г. Москва

заместитель директора по научно-клинической работек.м.н; ФГУ «ГНЦД Росмедтехнологий», г. Москва

N FRIGO

ФГУ «ГНЦД Росмедтехнологий», г. Москва

гл. научный сотрудникд.м.н; ФГУ «ГНЦД Росмедтехнологий», г. Москва

N KAGANOVA

ФГУ «ГНЦД Росмедтехнологий», г. Москва

младший научный сотрудник; ФГУ «ГНЦД Росмедтехнологий», г. Москва

L ZNAMENSKAYA

ФГУ «ГНЦД Росмедтехнологий», г. Москва

заведующая отделом дерматологиик.м.н; ФГУ «ГНЦД Росмедтехнологий», г. Москва

A KUBANOV

ФГУ «ГНЦД Росмедтехнологий», г. Москва

заместитель директора по научной работед. м.н., профессор; ФГУ «ГНЦД Росмедтехнологий», г. Москва

参考

  1. Гинтер Е.А. Эволюция представлений о генетической природе мультифакториальных заболеваний. // Медицинская генетика. 2003. Т. 2. № 4. С. 146-156.
  2. Campalani E., Barker J. The clinical genetics of psoriasis. // Current Genomics. 2005. V. 6. P. 51-60.
  3. Скрипкин Ю.К., Мордовцев В.Н. Кожные и венерические болезни: Руководство для врачей. - М: Медицина, 1999. С. 116-118.
  4. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. // Ann. Rheum. Dis. 2004. Jul. N. 63(7). P. 755-8.
  5. Zhang M., Tracey K.J. Tumor necrosis factor. In: Thompson A.W. // In: The cytokine handbook, 3rd ed. New York. Academic press. 1998. 515-548.
  6. Cordiali-Fei P., Trento E., 'Agosto G.D. et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in sera and skin lesions. // Ann N Y Sci. 2007. Sep. Vol. 1110. P. 578-589.
  7. Saraceno R., Schipani C., Mazzota A. et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. // Pharmacol Res. 2008. Apr. Vol. 57, № 4. P. 290-295.
  8. Cordoro K.M., Feldman S.R. TNF-a Inhibitors in Dermatology. // Skin Therapy Lett. 2007. Sep. № 12(7). P. 4-6.
  9. Nash P.T., Florin T.H.J. Tumour necrosis factor inhibitors. // MJA. 2005. № 183(4). P. 205-208.
  10. Nikas S.N., Voulgari P.V., Takalou I.P. et al. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immuno-suppressive drugs, after infliximab treatment. // Ann. Rheum. Dis. 2005. Nov. № 64(11). P. 1665-7.
  11. Kalow W., Tang B.K., Endrenyi L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. // Pharmacogenetics. 1998. № 8. P. 283-289.
  12. Evans W.E., McLeod H.L. Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects. // NEJM. 2003. Feb. № 6. P. 538-549.
  13. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. // Dermatologica. 1978. № 157. P. 238-44.
  14. Bio-Rad Laboratories. Bio-Plex Human Cytokine, Chemokine, and Growth Factor Assays. Bulletin 5828.
  15. J. C. Caruso, N. Cliff, Empirical Size, Coverage, and Power of Confidence Intervals for Spearman's Rho//, Ed. and Psy. Meas. 57 (1997) pp. P. 637-654.
  16. Goodman L.A., Kruskal W.H. Measures of association for cross-classifications. // Journal of the American Statistical Association 49. 1954. P. 732-764.
  17. Reich K., Mössner R., König I.R.et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. // J Invest Dermatol. 2002. Jan. Vol. 118, № 1. P. 155-163.
  18. Nedoszytko B., Szczerkowska-Dobosz A., Zablotna M.et al. Association of promoter region polymorphisms in the tumor necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern polish population. // Br J Dermatol. 2007. Jul. Vol. 157, № 1. P. 165-167.
  19. Kaluza W., Reuss E., Grossmann S.et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. //J Invest Dermatol. 2000. Jun. Vol. 114, № 6. P. 1180-1183.
  20. Mascheretti S., Hampe J., Kühbacher T.et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. // Pharmacogenomics J. 2002. Vol. 2, № 2. P. 127-136.
  21. Fabris M., Di Poi E., Sacco S.et al. TNF-alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-alpha agents: preliminary results. // Reumatismo. 2002. Vol. 54, № 1. P. 19-26.
  22. Shetty A., Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. // Am J Pharmacogenomics. 2002. Vol. 2, № 4. P. 215-221.
  23. Matsukura H., Ikeda S., Yoshimura N.et al. Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRSF1B) affect responses to infliximab in Crohn's disease patients in Japan. // Aloment Pharmacol Ther. 2008. May. № 27(9). P. 765-770.
  24. Heidenreich R., Röcken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. // Int J Exp Pathol. 2009. Vol. 90, № 3. P. 232-48.
  25. Asadullah K., Sterry W., Stephanek K.et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. //J Clin Invest. 1998. Vol. 101, № 4. P. 783-794.
  26. Baran W., Szepietowski J.C., Mazur G. et al. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. // Acta Derm Venereol. 2008. Vol. 88, № 2. P. 113-116.
  27. Rashmi R., Rao K.S.J., Basavaraj K.H. A comprehensive review of biomarkers in psoriasis. // Clinical and Experimental Dermatology. 2009. № 34. P. 658-663.
  28. Goldstein A.M. Changing paradigms in dermatology: proteomics: a new approach to skin disease. // Clin Dermatol. 2003. Vol. 21, № 5. P. 370-374.
  29. Semprini S., Capon F., Tacconelli A. Evidence for differential S100 gene over - expression in psoriatic patients from genetically heterogeneous pedigrees. // Hum. Genetics. 2002. V. 111. P. 310-313.
  30. Broome A.M., Ryan D., Eckert R.L. S100 protein subcellular localization during epidermal differentiation and psoriasis. // J His-tochem Cytochem. 2003. 51. P. 675-685.
  31. Zibert J.R., Skov L., Thyssen J.P. et al. (2009) // J. Invest. Dermatol. (epub ahead of print).
  32. Aceto A., Caccuri A.M., Sacchetta P. et al. Dissociation and unfolding of Pi-class glutathione transferase. Evidence for a monomeric inactive intermediate. // Biochem J. 1992. July. 1. 285(Pt 1). P. 241-245.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © KUBANOVA A.A., LESNAYA I.N., FRIGO N.V., KAGANOVA N.L., ZNAMENSKAYA L.F., KUBANOV A.A., 2010

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).